Infection of macaques with simian immunodeficiency virus induces a species-specific antibody response to major histocompatibility complex class I and class II molecules

Journal of General Virology

Volumn 84, Issue 7, 2003, Pages 1671-1676

  Polyanskaya, Natasha ^a   Sharpe, Sally A ^a   Cook, Nicola ^a   Leech, Sharon ^a   Cranage, Martin P ^a,b  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROTEIN; INACTIVATED VIRUS VACCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ALPHA CHAIN; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIGEN RECOGNITION; ARTICLE; BLOOD ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSS REACTION; DRUG TARGETING; HOST CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNE RESPONSE; MACACA; MAJOR HISTOCOMPATIBILITY COMPLEX; MOLECULAR MIMICRY; NONHUMAN; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; RETROVIRUS; RHESUS MONKEY; SIMIAN IMMUNODEFICIENCY VIRUS; SPECIES DIFFERENCE; VACCINATION; VIRUS ENVELOPE; VIRUS INACTIVATION;

ANIMALS; ANTIBODIES, VIRAL; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; MACACA MULATTA; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; SPECIES SPECIFICITY;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS; MACACA; MACACA MULATTA; RNA VIRUSES; SIMIAE; SIMIAN IMMUNODEFICIENCY VIRUS; UNIDENTIFIED RETROVIRUS;

EID: 0037483017     PISSN: 00221317     EISSN: None     Source Type: Journal    
DOI: 10.1099/vir.0.18989-0     Document Type: Article

References (38)

1. Arthur, L. O., Bess, J. W., Jr, Sowder, R. C., II, Benveniste, R. E., Mann, D. L., Chermann, J. C.&Henderson, L. E. (1992). Cellular proteins bound to immunodeficiency viruses: implications for pathogenesis and vaccines. Science 258, 1935-1938.
2. Arthur, L. O., Bess, J. W., Jr, Urban, R. G., Strominger, J. L., Morton, W. L., Mann, D. L., Henderson, L. E.&Benveniste, R. E. (1995). Macaques immunized with HLA-DR are protected from challenge with simian immunodeficiency virus. J Virol 69, 3117-3124.
3. Benkirane, M., Blanc-Zouaoui, D., Hirn, M.&Devaux, C. (1994). Involvement of human leukocyte antigen class I molecules in human immunodeficiency virus infection of CD4-positive cells. J Virol 68, 6332-6339.
4. Bergmeier, L. A., Walker, J., Tao, L., Cranage, M.&Lehner, T. (1994). Antibodies to human and non-human primate cellular and culture medium components in macaques vaccinated with the simian immunodeficiency virus. Immunology 83, 213-220.
5. Cantin, R., Fortin, J.-F., Lamontagne, G.&Tremblay, M. (1997). The presence of host-derived HLA-DR1 on human immunodeficiency virus type 1 increases viral infectivity. J Virol 71, 1922-1930.
6. Cantin, R., Martin, G.&Tremblay, M. J. (2001). A novel virus capture assay reveals a differential acquisition of host HLA-DR by clinical isolates of human immunodeficiency virus type 1 expanded in primary human cells depending on the nature of producing cells and the donor source. J Gen Virol 82, 2979-2987.
7. Chan, W. L., Rodgers, A., Hancock, R. D., Taffs, F., Kitchin, P., Farrar, G.&Liew, F. Y. (1992). Protection of simian immunodeficiency virus-vaccinated monkeys correlates with anti-HLA class I antibody response. J Exp Med 176, 1203-1207.
8. mac-32H. AIDS 9, 223-228.
9. Cranage, M. P., Baskerville, A., Ashworth, L. A. E.&7 other authors (1992a). Intrarectal challenge of macaques vaccinated with formalin-inactivated simian immunodeficiency virus. Lancet 339, 273-274.
10. Cranage, M. P., Ashworth, L. A. E., Greenaway, P. J., Murphey-Corb, M.&Desrosiers, R. C. (1992b). AIDS vaccine developments. Nature 355, 685-686.
11. Cranage, M. P., Polyanskaya, N., McBride, B.&12 other authors (1993). Studies on the specificity of the vaccine effect elicited by inactivated simian immunodeficiency virus. AIDS Res Hum Retrovir 9, 13-22.
12. Daniel, V., Schimpf, K.&Opelz, G. (1989). Lymphocyte autoantibodies and alloantibodies in HIV-positive haemophilia patients. Clin Exp Immunol 75, 178-183.
13. De La Barrera, S., Fainboim, L., Lugo, S., Picchio, G. R., Muchnik, G. R.&De Bracco, M. M. E. (1987). Anti-class II antibodies in AIDS patients and AIDS-risk groups. Immunology 62, 599-604.
14. De Santis, C., Robbioni, P., Longhi, R., Lopalco, L., Siccardi, A. G., Beretta, A.&Roberts, N. J., Jr (1993). Cross-reactive response to human immunodeficiency virus type 1 (HIV-1) gp120 and HLA class I heavy chains induced by receipt of HIV-1-derived envelope vaccines. J Infect Dis 168, 1396-1403.
15. De Santis, C., Lapalco, L., Robbioni, P., Longhi, R., Rappocciolo, G., Siccardi, A. G.&Beretta, A. (1994). Human antibodies to immunodominant C5 region of HIV-1 gp120 cross-react with HLA class I on activated cells. AIDS Res Hum Retrovir 10, 157-162.
16. Dorsett, B., Cronin, W., Chuma, V.&Iochim, H. L. (1985). Anti-lymphocyte antibodies in patients with the acquired immune deficiency syndrome. Am J Med 78, 621-626.
17. Fortin, J.-F., Cantin, R., Lamontagne, G.&Tremblay, M. (1997). Host-derived ICAM-1 glycoproteins incorporated on human immunodeficiency virus type 1 are biologically active and enhance viral infectivity. J Virol 71, 3588-3596.
18. Golding, H., Shearer, G. M., Hillman, K.&7 other authors (1989). Common epitope in human immunodeficiency virus (HIV) 1-gp41 and HLA class II elicits immunosuppressive autoantibodies capable of contributing to immune dysfunction in HIV 1-infected individuals. J Clin Invest 83, 1430-1435.
19. Grassi, F., Menervi, R., Gullberg, M.&9 other authors (1991). Human immunodeficiency virus type 1 gp120 mimics a hidden monomorphic epitope borne by class I major histocompatibility complex heavy chains. J Exp Med 174, 53-62.
20. Habeshaw, J. A. (1994). HLA mimicry by HIV-1 gp120 in the pathogenesis of AIDS. Immunol Today 15, 39-40.
21. Henderson, L. E., Sowder, R., Copeland, T. D., Oroszlan, S., Arthur, L. O., Robey, W. G.&Fischinger, P. J. (1987). Direct identification of class II histo-compatibility Dr proteins in preparations of human T-cell lymphotropic virus type III. J Virol 61, 629-632.
22. Hoxie, J. A., Fitzharris, T. P., Youngbar, P. R., Mathews, S. D. M., Rackowski, J. L.&Radka, S. F. (1987). Non-random association of cellular antigens with HTLV-III virions. Hum Immunol 18, 39-52.
23. Kion, T. A.&Hoffmann, G. W. (1991). Anti-HIV and anti-MHC antibodies in alloimmune and autoimmune mice. Science 253, 1138-1140.
24. Langlois, A. J., Weinhold, K. J., Mathews, T. J., Greenberg, M. L.&Bolognesi, D. P. (1992). Detection of anti-human cell antibodies in sera from macaques immunized with whole inactivated virus. AIDS Res Hum Retrovir 8, 1641-1652.
25. Meier, T., Arni, S., Malarkannan, S., Poincelet, M. & Hoessli, D. (1992). Immunodetection of biotinylated lymphocyte-surface proteins by enhanced chemiluminescence: a nonradioactive method for cell-surface protein analysis. Anal Biochem 204, 220-226.
26. Müller, C., Kukel, S., Schneweis, K. E.&Bauer, R. (1994). Anti-lymphocyte antibodies in plasma of HIV-1-infected patients preferentially react with MHC class II-negative T cells and are linked to antibodies against gp41. Clin Exp Immunol 97, 367-372.
27. Nguyen, D. H.&Hildreth, J. E. (2000). Evidence for budding of human immunodeficiency virus type 1 selectively from glycolipid-enriched membrane lipid rafts. J Virol 74, 3264-3272.
28. Ozturk, G. E., Kohler, P. F., Horsburgh, C. R., Jr & Kirkpatrick, C. H. (1987). The significance of anti-lymphocyte antibodies in patients with acquired immune deficiency syndrome (AIDS) and their sexual partners. J Clin Immunol 7, 130-139.
29. mac infection. AIDS Res Hum Retrovir 13, 923-931.
30. Poon, D. T., Coren, L. V.&Ott, D. E. (2000). Efficient incorporation of HLA class II onto human immunodeficiency virus type 1 requires envelope glycoprotein packaging. J Virol 74, 3918-3923.
31. + individuals. Immunol Lett 33, 99-104.
32. Rossio, J. L., Bess, J., Jr, Henderson, L. E., Cresswell, P. &Arthur, L. O. (1995). HLA class II on HIV particles is functional in superantigen presentation to human T cells: implications for HIV pathogenesis. AIDS Res Hum Retrovir 11, 1433-1439.
33. Saifuddin, M., Ghassemi, M., Patki, C., Parker, C. J. & Spear, G. T. (1994). Host cell components affect the sensitivity of HIV type 1 to complement-mediated virolysis. AIDS Res Hum Retrovir 10, 829-837.
34. Saifuddin, M., Parker, C. J., Peebles, M. E., Gorny, M. K., Zolla-Pazner, S., Ghassemi, M., Rooney, I. A., Atkinson, J. P.&Spear, G. T. (1995). Role of virion-associated glycosylphosphatidylinositol-linked proteins CD55 and CD59 in complement resistance of cell line-derived and primary isolates of HIV-1. J Exp Med 182, 501-509.
35. Spear, G. T., Olinger, G. G., Saifuddin, M.&Gebel, H. M. (2001). Human antibodies to major histocompatibility complex alloantigens mediate lysis and neutralization of HIV-1 primary isolate virions in the presence of complement. J Acquir Immune Defic Syndr 26, 103-110.
36. Stott, E. J. (1991). Anti-cell antibody in macaques. Nature 353, 393.
37. Stott, E. J., Almond, N., West, W., Kent, K., Cranage, M. P. &Rud, E. (1994). Protection against simian immunodeficiency virus infection of macaques by cellular or viral antigens. Neuviéme Colloque des Cent Gardes 219-224.
38. Tremblay, M. J., Fortin, J.-F.&Cantin, R. (1998). The acquisition of host-encoded proteins by nascent HIV-1. Immunol Today 19, 346-351.